Oncogenic osteomalacia: Localization of underlying peripheral mesenchymal tumors with use of Tc 99m sestamibi scintigraphy

Endocrine Practice

Volumn 12, Issue 1, 2006, Pages 35-42

  Hodgson, Stephen F ^a   Clarke, Bart L ^a   Tebben, Peter J ^a   Mullan, Brian P ^a   Cooney III, William P ^a   Shives, Thomas C ^a  

^a MAYO CLINIC ROCHESTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIAGNOSTIC AGENT; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M;

AGED; ARTICLE; BONE TUMOR; CONNECTIVE TISSUE TUMOR; EPIDEMIOLOGY; FEMALE; FOLLOW UP; HOSPITALIZATION; HUMAN; LIPOMA; MALE; MESODERM; MIDDLE AGED; OSTEOMALACIA; PATHOLOGY; RISK ASSESSMENT; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

AGED; BONE NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MESODERM; MIDDLE AGED; NEOPLASMS, ADIPOSE TISSUE; NEOPLASMS, CONNECTIVE TISSUE; OSTEOMALACIA; RISK ASSESSMENT; SAMPLING STUDIES; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; TECHNETIUM TC 99M SESTAMIBI;

EID: 33646844225     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.12.1.35     Document Type: Article

References (15)

1. Cai Q, Hodgson SF, Kao PC, et al. Brief report: inhibition of renal phosphate transport by a tumor product in a patient with oncogenic osteomalacia. N Engl J Med. 1994;330:1645-1649.
2. Econs MJ, Drezner MK. Tumor-induced osteomalacia - unveiling a new hormone. N Engl J Med. 1994;330:1679-1681.
3. Schiavi SC, Kumar R. The phosphatonin pathway: new insights in phosphate homeostasis. Kidney Int. 2004;65:1-14.
4. Parfitt A. Osteomalacia and related disorders. In: Avioli LV, Krane SM, eds. Metabolic Bone Disease and Clinically Related Disorders. 2nd ed. Philadelphia, PA: WB Saunders Company, 1990: 329-396.
5. Drezner MK. Tumor-induced osteomalacia. In: Favus MJ, ed. Primer on Metabolic Bone Diseases and Disorders of Mineral Metabolism. 4th ed. Philadelphia, PA: Lippincott Williams & Wilkins, 1999: 331-337.
6. Reid IR, Teitelbaum SL, Dusso A, Whyte MP. Hypercalcemic hyperparathyroidism complicating oncogenic osteomalacia: effect of successful tumor resection on mineral homeostasis. Am J Med. 1987;83:350-354.
7. Firth RG, Grant CS, Riggs BL. Development of hypercalcemic hyperparathyroidism after long-term phosphate supplementation in hypophosphatemic osteomalacia: report of two cases. Am J Med. 1985;78:669-673.
8. Casari S, Rossi V, Varenna M, et al. A case of oncogenic osteomalacia detected by 111In-pentetreotide total body scan. Clin Exp Rheumatol. 2003;21:493-496.
9. Garcia CA, Spencer RP. Bone and In-111 octreotide imaging in oncogenic osteomalacia: a case report. Clin Nucl Med. 2002;27:582-583.
10. Moran M, Paul A. Octreotide scanning in the detection of a mesenchymal tumour in the pubic symphysis causing hypophosphataemic osteomalacia. Int Orthop. 2002;26:61-62.
11. Jan de Beur SM, Streeten EA, Civelek AC, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet. 2002;359:761-763.
12. Rhee Y, Lee JD, Shin KH, Lee HC, Huh KB, Lim SK. Oncogenic osteomalacia associated with mesenchymal tumour detected by indium-111 octreotide scintigraphy. Clin Endocrinol (Oxf). 2001;54:551-554.
13. Avila NA, Skarulis M, Rubino DM, Doppman JL. Oncogenic osteomalacia: lesion detection by MR skeletal survey. AJR Am J Roentgenol. 1996;167:343-345.
14. Dissanayake AM, Wilson JL, Holdaway IM, Reid IR. Oncogenic osteomalacia: culprit tumour detection by whole body magnetic resonance imaging. Intern Med J. 2003;33:615-616.
15. Nelson AE, Mason RS, Robinson BG, et al. Diagnosis of a patient with oncogenic osteomalacia using a phosphate uptake bioassay of serum and magnetic resonance imaging. Eur J Endocrinol. 2001;145:469-476.